One should never take anything for granted, your own research is your friend.
Take 60 seconds to step back and have a look at where the company is on the path, clinical trials complete, approvals granted, labs built, user programmes satisfied, first sales made, and now sales ramp up just commencing. It's a long path with a big picture and a goal at the end.
If I truly ask myself whether 0.038% market share (1,000 sales), or a figure half that, or double that magnitude really matters at this time, the answer is, shrug, not one bit really in the big picture. On the path to 10% in five years it's a bit of early stage noise really.
The commercialisation plan and progress against it is important though and although Pacific Edge typically meet their milestones really very well we should watch for those to be on schedule.
If a nice preliminary 1,000 to 5,000 early sales are reported to 31 March and a confident affirmation of progress on the commercialisation plan is received from Pacific Edge, the share price should head nicely toward valuation, probably helped along by all those milestones anticipated for this year.